FDA Announces Draft Guidance for Biomarker-Total Kidney Volume in ADPKD Treatment

Summary

The FDA has released a draft guidance outlining the use of total kidney volume as a prognostic biomarker to identify patients with autosomal dominant polycystic kidney disease at high risk of renal function decline, enabling drug developers to streamline clinical trial submissions.